¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"trial of labor after cesarean section"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • frozen section
    µ¿°áÀýÆí
  • longitudinal section
    1. ¼¼·Î´Ü¸é, Á¾´Ü¸é 2. ¼¼·ÎÀý´Ü, Á¾´Ü
  • median section
    Á¤Áߴܸé
  • optical section
    ±¤ÇÐÀýÆí
  • paraffin section
    ÆÄ¶óÇÉÀýÆí
  • section
    1. Àý´Ü 2. ´Ü¸é 3. ÀýÆí 4. Àý°³
  • sagittal section
    1. ½Ã»óÀý´Ü 2. ½Ã»ó´Ü¸é
  • serial section
    1. ¿¬¼ÓÀýÆí 2. ¿¬¼Ó´Ü¸é
  • tangential section
    ºñ½ºµëÀý´Ü, Á¢¼±Àý´Ü
  • ultrathin section
    ÃʹÚÀýÆí
  • artificial labor
    ÀΰøºÐ¸¸
  • atonic labor
    ¹«±äÀåÁøÅë
  • complicated labor
    ÇÕº´ºÐ¸¸
  • dry labor
    °Ç¼ººÐ¸¸
  • difficult labor
    ³­»ê
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • preterm labor
    Á¶±âºÐ¸¸, Á¶±â»êÅë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • body section radiography
    (¢¡tomography) ´ÜÃþÃÔ¿µ¼ú
  • cross-section
    °¡·Î´Ü¸é
  • celloidin section
    ¼¿·ÎÀ̵òÀýÆí
  • cross section
    ´Ü¸éÀû, È®À²ÇÔ¼ö
  • cross section radiography
    (¢¡tomography) ´ÜÃþÃÔ¿µ¼ú
  • frozen section
    µ¿°áÀýÆí
  • longitudinal section
    ¼¼·Î´Ü¸é
  • optical section
    ±¤ÇÐÀýÆí
  • paraffin section
    ÆÄ¶óÇÉÀýÆí
  • section
    Àý´Ü, ´Ü¸é, ÀýÆí, Àý°³
  • sagittal section
    ½Ã»óÀý´Ü
  • serial section
    ¿¬¼ÓÀýÆí
  • tangential section
    ºñ½ºµëÀý´Ü
  • thin section
    ¾ãÀºÀýÆí, ¼¼ÀýÆí
  • transverse section
    °¡·Î´Ü¸é
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • after action
    ÈÄ(¼Ó)(ý­(áÙ))ÀÛ¿ë.
  • after care
    ÈÄÄ¡·á(ý­ö½èþ), Èĺ¸È£(ý­ÜÁûÞ), ȸº¹±âÄ¡·á, ȸº¹±âº¸È£.
  • after cataract
    ÈĹ߹鳻Àå.
  • after dribbling
    ÈÄÀÓÀû(ý­ìøîÙ).
  • after load
    ÈĺÎÇÏ(ý­Ý¶ùÃ).
  • after-depolarization
    ÈÄÅ»ºÐ±Ø(ý­÷­ÝÂп)
  • after-discharge
    ÈĹ߻ç(ý­Û¡ÞÒ) ¹Ý»çÀÇ
  • after-load
    ÈĺÎÇÏ(ý­Ý¶ùÃ)
  • after-movement
    ÈĿ(Ì·ËôËÄ).
  • after-nystagmus
    ÈĹ߾ÈÁø
  • after-pain
    ÈÄÁøÅë(ý­òæ÷Ô).
  • after-vision
    ÀÜ»ó½Ã°¢(íÑßÀò±ÊÆ).
  • positive after image
    ¾ç¼ºÀÜ»ó(åÕàõíÑßÀ).
  • positive after potential
    ¾ç¼ºÈÄÀüÀ§(åÕàõý­ï³êÈ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • trial-and-error learning
    ½ÃÇàÂø¿ÀÇнÀ(ãËú¼ó¹è¦æßã§).
  • after action
    ÈÄ(¼Ó)(ý­(áÙ))ÀÛ¿ë.
  • after care
    ÈÄÄ¡·á(ý­ö½èþ), Èĺ¸È£(ý­ÜÁûÞ), ȸº¹±âÄ¡·á, ȸº¹±âº¸È£.
  • after cataract
    ÈĹ߹鳻Àå.
  • after dribbling
    ÈÄÀÓÀû(ý­ìøîÙ).
  • after load
    ÈĺÎÇÏ(ý­Ý¶ùÃ).
  • after-depolarization
    ÈÄÅ»ºÐ±Ø(ý­÷­ÝÂп)
  • after-discharge
    ÈĹ߻ç(ý­Û¡ÞÒ) ¹Ý»çÀÇ
  • after-load
    ÈĺÎÇÏ(ý­Ý¶ùÃ)
  • after-movement
    ÈĿ(Ì·ËôËÄ).
  • after-nystagmus
    ÈĹ߾ÈÁø
  • after-pain
    ÈÄÁøÅë(ý­òæ÷Ô).
  • after-vision
    ÀÜ»ó½Ã°¢(íÑßÀò±ÊÆ).
  • nystagmus, optokinetic after [=OKAN]
    ½Ã¿îµ¿(¼º) ÈľÈÁø
  • optokinetic after nystagmus =OKAN
    ½Ã¼±À̵¿¼º ÈľÈÁø.
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • section thickness
    Àý´ÜµÎ²²
  • serial section
    ¿¬¼ÓÀýÆí
  • thin section
    ¾ãÀº ÀýÆí, ¼¼ÀýÆí
  • transverse section
    °¡·ÎÀý´Ü¸é, Ⱦ´Ü¸é
  • transverse section
    Ⱦ´Ü¸é
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
C sect, C-section cesarean section
FTP Failure To Progress, where dilation stalls or labor does not progress fast enough in the provider's ...
HBAC Home Birth After Cesarean
CS, Cs   1) Cycloserine
  2) Cesarean Section
C/S Cesarean Section
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CS Caesarian section
FS Frozen section
ILO International Labor Office
ILO International Labor Organisation
PTL Preterm labor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • tedious labor
    Áö»ê
  • after care
    ÈÄÄ¡·á, Èĺ¸È£, ȸº¹±â Ä¡·á, ȸº¹±â º¸È£, º´ÈÄ Ä¡·á, ÈÄ ¿ä¹ý
    1. º´ ¶Ç´Â ¼ö¼ú ÈÄÀÇ µÞ Á¶¸®. 2. ȸº¹±âÀÇ È¯ÀÚ Æ¯È÷ ¼ö¼úÀ» ¹ÞÀº ȯÀÚÀÇ °£È£¿Í Ä¡·á. 3. Á¦ 2Â÷ ¼¼°è´ëÀü ÀÌÀü¿¡´Â °áÇ٠ȯÀÚ°¡ ¸¹¾Æ ȸº¹±â ȯÀÚ¸¦ ´ë»óÀ¸·Î »çȸÀû ½ÃÃ¥À¸·Î¼­ ½ÃÀÛµÈ °ÍÀ̸ç, °Ç°­ °ü¸®¸¦ Çϸ鼭 ÀÛ¾÷ Áöµµ¸¦ Çϰųª ȯÀÚ°¡ ÀÏÇÒ ¼ö ÀÖ´Â Á÷Àåȯ°æÀ» Á¶¼ºÇϰųª Çß´Ù. ¿À´Ã³¯¿¡´Â ÀçȰ ÀÇÇп¡ À־ ³úÁ¹Áß µî¿¡ ´ëÇØ ¾ÖÇÁÅÍ ÄɾîÀÇ ´Ü¾î°¡ »ç¿ëµÇ´Â ¼ö°¡ ÀÖ´Ù.
  • after cataract
    ÈÄ¹ß ¹é³»Àå
    ¼öÁ¤Ã¼ ³¶À» ÀûÃâÇϰųª ¿Ü»ó¼º ¹é³»Àå¿¡¼­ ¼öÁ¤Ã¼ ¹°ÁúÀÌ Èí¼öµÈ ´ÙÀ½¿¡ Èij¶°ú Àü³¶ÀÇ ÀϺΰ¡ ³²°í ¿©±â¿¡ ¼öÁ¤Ã¼ ¼¶À¯ ¶Ç´Â »óÇÇÀÇ ÀϺΰ¡ ºÙ¾îÀÖ°Ô µÇ¸é ȥŹÇÑ ¸·ÀÌ Çü¼ºµÈ´Ù. Ä¡·á·Î´Â Àý°³¼úÀÌ Àִµ¥ À̰ÍÀº ½Ã·Â Àå¾Ö³ª, ¾ÈÀúÀÇ °Ë»ç°¡ °ï¶õÇÒ ¶§ ¶Ç´Â ´Ü¾È º¹½Ã°¡ ÀÖÀ» ¶§ ¼ö¼ú·Î¼­ µ¿°øºÎÀÇ È¥Å¹µÈ ¸·¿¡ ÀÎÀ§ÀûÀ¸·Î ±¸¸ÛÀ» ¸¸µé¾îÁÖ´Â °ÍÀÌ´Ù.
  • after dribbling
    ÈÄÀÓÀû
  • after image
    ˆȗ
    ½Ã°¢ÀÇ ¿¹¹Î¼ºÀ¸·Î ÀÎÇØ ¿ÜºÎ·ÎºÎÅÍÀÇ ÀÚ±ØÀÌ »ç¶óÁø ÈÄ¿¡µµ ³²¾ÆÀÖ´Â ÈïºÐÀ¸·Î ÀÎÇØ ½Ã ÀÚ±ØÀÌ ¿¬ÀåµÇ°Å³ª »õ·Î¿öÁö´Â ´À³¦.
  • after load
    ÈÄ ºÎÇÏ
  • after-care
    ÈÄ Ä¡·á, ÈÄ º¸È£, ȸº¹±â Ä¡·á, ȸº¹±â º¸È£
    º´À̳ª ¼ö¼ú ÈÄÀÇ µÞÁ¶¸®. ȸº¹±âÀÇ È¯ÀÚ, ƯÈ÷ ¼ö¼úÀ» ¹ÞÀº ȯÀÚÀÇ °£È£¿Í Ä¡·á.
  • after-discharge
    ÈÄ¹ß»ç ¹Ý»çÀÇ
    ÀÚ±ØÀÌ ³¡³­ µÚ¿¡µµ ÀÓÆÞ½ºÀÇ ¹ß»ýÀÌ Áö¼ÓµÇ´Â °Í.
  • after-load
    ÈÄ ºÎÇÏ
    ½É±Ù ¼öÃà Áß¿¡ ½É±Ù¿¡ °É·Á ÀÖ´Â ºÎÇÏ·®¿¡¼­ ÀüºÎÇÏ·®À» »« ¾çÀÌ´Ù.
  • after-nystagmus
    ÈÄ¹ß ¾ÈÁø
  • after-potential
    ÈÄ ÀüÀ§ Çö»ó
    ½ºÆÄÀÌÅ© ÀüÀ§ µÚ¿¡ º¼ ¼ö ÀÖ´Â ÀüÀ§ º¯µ¿ÀÌ´Ù. À½¼º ÈÄ ÀüÀ§¿Í ¾ç¼º ÈÄ ÀüÀ§·Î ³ª´¶´Ù. ÀüÀÚ´Â ¿ªÄ¡ÀÇ »ó½Â, ÈÄÀÚ´Â Çϰ­À» ÀÏÀ¸Å²´Ù.
  • after-sensation
    ÈÄ °¨°¢
    ¿øÀÎÀÌ µÇ¾ú´ø ÀÚ±ØÀÌ Á¦°ÅµÈ ÈÄ¿¡µµ °è¼ÓµÇ´Â Áö°¢.
  • after-vision
    ÀÜ»ó ½Ã°¢
    ÀÚ±ØÀÌ ±×Ä£ ÈÄ¿¡ ³²¾ÆÀÖ´Â ½Ã°¢ÀÇ ÀÜÁ¸.
  • optokinetic after nystagmus
    ½Ã ¿îµ¿ ÈÄ ¾ÈÁø, ½Ã ¿îµ¿¼º ÈÄ ¾ÈÁø
  • positive after potential
    ¾ç¼º ÈÄÀüÀ§
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
Bernoulli trial A single random event for which there are two and only two possible outcomes that are mutually exclusive and have a priori fixed (and complementary) probabilities of resulting. The trial is the realization of this process. Conventionally one outcome is termed a success and is assigned the score 1, the other is a failure and has the score zero. Thus the outcome might be 0 (no heads, one tail) or 1 (1 head, no tails).
(05 Mar 2000)
randomised controlled trial A clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and a trial employing any of these techniques for patient assignment is designated simply a controlled clinical trial.
(12 Dec 1998)
randomised trial <statistics> A clinical trial in which patients have been randomly assigned to receive either the study drug or alternative treatment, in which neither the patient nor the physician conducting the study know which treatment is being given the patient, and in which the alternative to the study drug is a placebo, the study is conducted at several centres.
(09 Oct 1997)
phase I clinical trial <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose.
They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies.
The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs.
(31 Dec 1997)
phase II clinical trial <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study.
(31 Dec 1997)
phase III clinical trial <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments.
Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials.
(31 Dec 1997)
clinical trial <pharmacology> Research study conducted with patients, usually to evaluate a new treatment or drug. Each trial is designed to answer scientific questions and to find better ways to treat individuals with a specific disease.
(12 May 1997)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
controlled clinical trial A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials.
(12 Dec 1998)
controlled trial A clinical study in which one group of participants receives an experimental drug while another group receives either a placebo or an approved standard therapy. When participants do not know which group they are in, the trial is blinded.
See: Double-Blind.
(09 Oct 1997)
prospective, randomised, double-blind clinical trial <statistics> A clinical trial in which the method for analysing data has been specified in the protocol before the study has begun (prospective), the patients have been randomly assigned to receive either the study drug or alternative treatment, and in which neither the patient nor the physician conducting the study know which treatment is being given to the patient.
(13 Nov 1997)
human clinical trial <pharmacology> Controlled clinical studies in human volunteers to test the safety and efficacy of pharmaceutical candidates.
There are usually three distinct phases of human clinical testing: Phases I, II, and III.
Phase I trials are safety studies of volunteers, usually healthy controls. Phase II trials are studies to confirm safety and study optimum dose and initial efficacy. Phase III trials are studies to prove safety and efficacy in a specific patient population.
(14 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inquire after
    ¾ÈºÎ¸¦ ¹¯´Ù
  • keep after
    ³¡±îÁö ÂÑ´Ù
  • look after
    µ¹º¸´Ù
  • run after
    ÃßÀûÇÏ´Ù; µû¶ó´Ù´Ï´Ù
  • section
    Àý°³
  • take after
    -¸¦ ´à´Ù
  • Caesarean section(operation)
    (Julius Caesar°¡ ÀÌ ¹æ¹ýÀ¸·Î ž´Ù´Â Àü¼³¿¡¼­)Á¦¿ÕÀý°³ ¼ö¼ú;°³º¹ ºÐ¸¸¹ý
  • after
    (...ÀÇ)µÚ¿¡;...ÇÏ¿´À¸¹Ç·Î;...ÇÏ°í³ª¼­;...À» ã¾Æ¼­;...¿¡ µû¶ó¼­
  • conic section
    ¿ø»Ô °î¼±;¿ø»Ô°î¼±·Ð
  • corss-section paper
    ¸ð´« Á¾ÀÌ
  • cross section
    °¡·ÎÀÚ¸£±â;Ⱦ´Ü¸é;´Ü¸éµµ;(»çȸ µîÀÇ)´ëÇ¥ÀûÀÎ ¸é;´Ü¸é
  • golden section
    Ȳ±Ý ºÐÇÒ
  • morning after
    ¼÷Ãë;(¾Ç¿¡¼­ÀÇ)´µ¿ìħ
  • quarter section
    ¹Ý ¸¶ÀÏ 4¹æÀÇ ÅäÁö
  • rhythm section
    (¹êµåÀÇ)¸®µë ´ã´ç ±×·ì(ÇǾƳë.±âŸ.º£À̽º.µå·³)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á